Click here to read the Cover Story, "Experts offer opinions on global trends in retina, part 2."
Clinical trials have clearly laid out treatment protocols, usually with monthly treatment intervals, and the subjects tend to be compliant and motivated for the study visits. In the real world, life gets in the way.
Treatment burden, such as the distance needed to travel, transportation, time, cost, illnesses, physician access and now the fear of COVID-19, may all contribute to undertreatment. How can we improve on this? One method I propose is early disease detection and personalized treatment
Uncategorized